학술논문
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19
Document Type
Article
Author
Allerton, C.M.N.; Greenfield, S.R.; Kalgutkar, A.S.; Lovett, G.H.; Owen, D.R.; Patel, N.C.; Sammons, M.F.; Tuttle, J.B.; Verhoest, P.R.; Yang, Q.; Arcari, J.T.; Aschenbrenner, L.M.; Avery, M.; Bechle, B.M.; Buzon, L.M.; Catlin, N.R.; Carlo, A.A.; Coffman, K.J.; Dantonio, A.; Di, L.; Eng, H.; Farley, K.A.; Gernhardt, S.S.; Kimoto, E.; Lanyon, L.F.; Lian, Y.; Martínez Alsina, L.A.; Noell, S.; Obach, R.S.; Rai, D.K.; Reese, M.R.; Sharma, R.; Steppan, C.M.; Wei, L.; Behzadi, M.A.; Cardin, R.D.; Rothan, H.A.; Sathish, J.G.; Yurgelonis, I.; Zhu, Y.; Boras, B.; Ferre, R.A.; Greasley, S.E.; Liu, W.; Sakata, S.; Gibson, S.A.; Hurst, B.L.
Source
In: Journal of Medicinal Chemistry . (Journal of Medicinal Chemistry, 22 August 2024, 67(16):13550-13571)
Subject
Language
English
ISSN
15204804
00222623
00222623